FOLFIRINOX is a combination chemotherapy regimen used in the treatment of advanced pancreatic cancer. It consists of four different drugs: folinic acid, fluorouracil, irinotecan, and oxaliplatin. This regimen has been shown to be effective in improving overall survival and progression-free survival in patients with advanced pancreatic cancer compared to other chemotherapy regimens. FOLFIRINOX is often used as a first-line treatment for patients who are eligible to tolerate the side effects of the regimen. Common side effects of FOLFIRINOX include nausea, vomiting, diarrhea, and low blood cell counts.